Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1

J. H. Yim, B. A. Siegel, M. K. DeBenedetti, J. A. Norton, T. C. Lairmore, G. M. Doherty

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Background. Neuroendocrine tumors (NETs) are a potentially lethal component of multiple endocrine neoplasia type 1 (MEN 1). Somatostatin receptor scintigraphy (SRS) can be used to localize NETs and evaluate patients for extraduodenopancreatic disease; its utility in managing MEN 1 is undefined. Methods. All patients with MEN 1 evaluated by SRS from April 1994 to November 1997 are reported. SRS findings were correlated with other imaging studies and operative findings. Results. Thirty-seven SRS studies were performed in 29 patients with MEN 1. SRS identified occult tumor in 36% (4/11) of patients with only biochemical evidence of NET; 2 patients went on to resection. SRS showed tumor in 79% (15/19) of patients with computed tomography (CT)-demonstrated tumor; 30% (6/20) of the SRS lesions were occult on CT. Conversely, 55% (16/29) of CT-identified lesions were occult on SRS. SRS found distant disease in 21% (6/29) of patients. In patients who had previous operations, SRS found tumor in 40% (4/10) of patients, again with both new positive and false-negative results compared with other imaging. SRS also had 3 important false-positive results, including 1 patient who had laparotomy with no tumor identified. Conclusions. SRS is useful in identifying otherwise occult NETs in patients with MEN 1 and can substantially alter management. However SRS also has significant false- positive and false-negative results that demand correlation with other studies.

Original languageEnglish
Pages (from-to)1037-1042
Number of pages6
JournalSurgery
Volume124
Issue number6
DOIs
StatePublished - Jan 1 1998

Fingerprint Dive into the research topics of 'Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1'. Together they form a unique fingerprint.

Cite this